Detailed data from Novo Nordisk’s comparative Devote study confirms that the company’s new insulin is as safe as and markedly more effective than its rival, the top-selling Lantus from Sanofi. This information can strengthen Novo’s position in the important ongoing negotiations with US payers.
BY MARTIN HAVTORN PETERSEN Offentliggjort 14.06.17 kl. 20:34
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.
The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.